S&P 500   5,015.60 (+0.09%)
DOW   37,961.30 (+0.49%)
QQQ   420.93 (-0.59%)
AAPL   165.98 (-0.63%)
MSFT   403.65 (-0.15%)
META   494.29 (-1.50%)
GOOGL   154.50 (-0.97%)
AMZN   177.59 (-0.91%)
TSLA   148.60 (-0.89%)
NVDA   837.10 (-1.13%)
AMD   151.34 (-2.41%)
NIO   3.86 (-3.50%)
BABA   68.58 (-0.44%)
T   16.34 (+0.06%)
F   12.15 (+0.75%)
MU   109.95 (-1.77%)
GE   152.24 (-0.46%)
CGC   7.89 (+0.77%)
DIS   111.98 (-0.40%)
AMC   2.85 (-2.40%)
PFE   25.43 (+0.16%)
PYPL   62.14 (+0.06%)
XOM   119.73 (+1.02%)
S&P 500   5,015.60 (+0.09%)
DOW   37,961.30 (+0.49%)
QQQ   420.93 (-0.59%)
AAPL   165.98 (-0.63%)
MSFT   403.65 (-0.15%)
META   494.29 (-1.50%)
GOOGL   154.50 (-0.97%)
AMZN   177.59 (-0.91%)
TSLA   148.60 (-0.89%)
NVDA   837.10 (-1.13%)
AMD   151.34 (-2.41%)
NIO   3.86 (-3.50%)
BABA   68.58 (-0.44%)
T   16.34 (+0.06%)
F   12.15 (+0.75%)
MU   109.95 (-1.77%)
GE   152.24 (-0.46%)
CGC   7.89 (+0.77%)
DIS   111.98 (-0.40%)
AMC   2.85 (-2.40%)
PFE   25.43 (+0.16%)
PYPL   62.14 (+0.06%)
XOM   119.73 (+1.02%)
S&P 500   5,015.60 (+0.09%)
DOW   37,961.30 (+0.49%)
QQQ   420.93 (-0.59%)
AAPL   165.98 (-0.63%)
MSFT   403.65 (-0.15%)
META   494.29 (-1.50%)
GOOGL   154.50 (-0.97%)
AMZN   177.59 (-0.91%)
TSLA   148.60 (-0.89%)
NVDA   837.10 (-1.13%)
AMD   151.34 (-2.41%)
NIO   3.86 (-3.50%)
BABA   68.58 (-0.44%)
T   16.34 (+0.06%)
F   12.15 (+0.75%)
MU   109.95 (-1.77%)
GE   152.24 (-0.46%)
CGC   7.89 (+0.77%)
DIS   111.98 (-0.40%)
AMC   2.85 (-2.40%)
PFE   25.43 (+0.16%)
PYPL   62.14 (+0.06%)
XOM   119.73 (+1.02%)
S&P 500   5,015.60 (+0.09%)
DOW   37,961.30 (+0.49%)
QQQ   420.93 (-0.59%)
AAPL   165.98 (-0.63%)
MSFT   403.65 (-0.15%)
META   494.29 (-1.50%)
GOOGL   154.50 (-0.97%)
AMZN   177.59 (-0.91%)
TSLA   148.60 (-0.89%)
NVDA   837.10 (-1.13%)
AMD   151.34 (-2.41%)
NIO   3.86 (-3.50%)
BABA   68.58 (-0.44%)
T   16.34 (+0.06%)
F   12.15 (+0.75%)
MU   109.95 (-1.77%)
GE   152.24 (-0.46%)
CGC   7.89 (+0.77%)
DIS   111.98 (-0.40%)
AMC   2.85 (-2.40%)
PFE   25.43 (+0.16%)
PYPL   62.14 (+0.06%)
XOM   119.73 (+1.02%)
Free Trial

Innate Pharma (IPHYF) News Today

→ Explore the Future: Unlock the Top 3 AI Stocks for 2024 Report (From Darwin) (Ad)
Free IPHYF Stock Alerts
$2.65
0.00 (0.00%)
(As of 04/18/2024 ET)
Compare
Stock AnalysisChartFinancialsHeadlinesSEC FilingsShort Interest
SourceHeadline
markets.businessinsider.com logoBuy Rating Affirmed for Innate Pharma Amidst Promising Platforms and Strategic Growth Potential
markets.businessinsider.com - April 16 at 8:16 AM
marketbeat.com logoInnate Pharma (OTCMKTS:IPHYF) Stock Price Up 2.7%
marketbeat.com - April 3 at 12:23 AM
markets.businessinsider.com logoAnalysts Offer Insights on Healthcare Companies: Innate Pharma SA (OtherIPHYF), Medios AG (OtherMEDOF) and Tecan Group AG (OtherTCHBF)
markets.businessinsider.com - March 23 at 4:01 AM
benzinga.com logoInnate Pharma Stock (OTC:IPHYF), Insider Trading Activity
benzinga.com - February 26 at 9:30 PM
markets.businessinsider.com logoInnate Pharma SA (IPHYF) Receives a Hold from Kepler Capital
markets.businessinsider.com - February 4 at 1:32 AM
seekingalpha.com logoInnate Pharma: Worth A Deeper Look
seekingalpha.com - January 11 at 12:11 PM
markets.businessinsider.com logoAnalysts Conflicted on These Healthcare Names: Innate Pharma SA (OtherIPHYF), Amgen (AMGN) and Regeneron (REGN)
markets.businessinsider.com - January 6 at 9:24 AM
marketwatch.com logoInnate Pharma Up 4% After FDA Lifts Partial Clinical Hold on Lacutamab
marketwatch.com - January 4 at 1:44 PM
marketbeat.com logoShort Interest in Innate Pharma S.A. (OTCMKTS:IPHYF) Expands By 650.0%
marketbeat.com - December 28 at 3:59 PM
msn.com logoInnate Pharma and Sanofi to license natural killer cell engager
msn.com - December 19 at 5:26 AM
markets.businessinsider.com logoBuy Rating for Innate Pharma Backed by Promising Lacutamab Clinical Results and Regulatory Prospects
markets.businessinsider.com - December 14 at 1:30 AM
finance.yahoo.com logoInnate Pharma to Host Virtual KOL Event on Lacutamab
finance.yahoo.com - November 27 at 8:11 AM
finance.yahoo.com logoInnate Pharma Announces Conference Call for Third Quarter 2023 Business Update
finance.yahoo.com - November 7 at 1:35 AM
finance.yahoo.com logoInnate Pharma Announces Its Participation to Upcoming Investor Conferences
finance.yahoo.com - October 27 at 1:34 AM
finance.yahoo.com logoInnate Pharma Announces Abstracts Selected for ESMO Congress 2023
finance.yahoo.com - October 16 at 7:17 AM
marketwatch.com logoInnate Pharma Shares Fall Premarket on FDA Partial Study Hold
marketwatch.com - October 5 at 9:52 AM
msn.com logoRegulatory Hurdle For Innate Pharma's Blood Cancer Studies
msn.com - October 5 at 9:52 AM
markets.businessinsider.com logoInnate Pharma Says FDA Places Partial Clinical Hold On Lacutamab IND; Stock Down 10%
markets.businessinsider.com - October 5 at 9:52 AM
finance.yahoo.com logoInnate Pharma Announces Encore Presentation of Interim Results of Phase 2 TELLOMAK Study With Lacutamab With Updated Olsen 2022 Criteria at the EORTC Cutaneous Lymphoma Tumour Group Annual Meeting 2023
finance.yahoo.com - September 22 at 8:31 AM
finance.yahoo.com logoFirst Patient Dosed in SAR’514 / IPH6401 Phase 1/2 Clinical Trial in Relapsed/Refractory Multiple Myeloma
finance.yahoo.com - July 11 at 1:15 AM
finance.yahoo.com logoNumber of Shares and Voting Rights of Innate Pharma as of July 1, 2023
finance.yahoo.com - July 7 at 7:39 AM
markets.businessinsider.com logoKepler Capital Reaffirms Their Hold Rating on Innate Pharma SA (IPHYF)
markets.businessinsider.com - June 18 at 12:14 AM
marketwatch.com logoADRs End Higher, Innate Pharma and Medigus Trade Actively
marketwatch.com - June 8 at 8:54 PM
marketwatch.com logoInnate Pharma Shares Rise 8% After Cancer Treatment Gets Fast Track Designation
marketwatch.com - June 8 at 10:53 AM
finance.yahoo.com logoInnate Pharma Highlights Phase 1/2 Dose Escalation Safety and Preliminary Efficacy of Sanofi Developed First NK Cell Engager SAR’579 / IPH6101 in R/R AML
finance.yahoo.com - May 26 at 1:07 AM
finance.yahoo.com logoInnate Pharma to Present IPH6501 Preclinical Data at The EHA 2023 Congress
finance.yahoo.com - May 15 at 4:16 AM
markets.businessinsider.com logoH.C. Wainwright Reaffirms Their Buy Rating on Innate Pharma (IPHA)
markets.businessinsider.com - May 11 at 8:44 AM
finance.yahoo.com logoInnate Pharma Reports First Quarter 2023 Financial Results and Business Update
finance.yahoo.com - May 10 at 2:41 AM
finance.yahoo.com logoInnate Pharma Establishes a New At-The-Market ("ATM") Program on Nasdaq
finance.yahoo.com - April 26 at 5:34 PM
markets.businessinsider.com logoSVB Securities Keeps Their Buy Rating on Innate Pharma (IPHA)
markets.businessinsider.com - April 12 at 2:27 AM
finance.yahoo.com logoInnate Pharma Files Its 2022 Universal Registration Document (Document d’enregistrement universel) and 2022 Annual Report on Form 20-F
finance.yahoo.com - April 6 at 1:32 AM
markets.businessinsider.com logoInnate Pharma SA (IPHYF) Gets a Hold from Kepler Capital
markets.businessinsider.com - April 4 at 11:34 PM
msn.com logoInnate stock surges ~15% after license deal with Takeda
msn.com - April 3 at 12:05 PM
finance.yahoo.com logoInnate Pharma Announces Exclusive License of Antibodies to Takeda for Celiac Disease Research Program
finance.yahoo.com - April 3 at 2:01 AM
seekingalpha.com logoInnate Pharma S.A. 2022 Q4 - Results - Earnings Call Presentation
seekingalpha.com - March 29 at 9:00 PM
markets.businessinsider.com logoSVB Securities Reaffirms Their Buy Rating on Innate Pharma (IPHA)
markets.businessinsider.com - March 28 at 8:40 AM
finance.yahoo.com logoInnate Pharma Reports Full Year 2022(1) Financial Results and Business Update
finance.yahoo.com - March 23 at 4:27 AM
finance.yahoo.com logoInnate Pharma Provides Update on Silicon Valley Bank Exposure
finance.yahoo.com - March 13 at 2:35 AM
finance.yahoo.com logoNumber of Shares and Voting Rights of Innate Pharma as of February 1, 2023
finance.yahoo.com - February 21 at 9:59 AM
finanznachrichten.de logoInnate Pharma SA: Innate Pharma Announces HSR Clearance Regarding Expansion of Its Collaboration With Sanofi on NK Cell Engagers
finanznachrichten.de - January 25 at 1:40 AM
finance.yahoo.com logoInnate Pharma Announces HSR Clearance Regarding Expansion of Its Collaboration With Sanofi on NK Cell Engagers
finance.yahoo.com - January 25 at 1:40 AM
finance.yahoo.com logoInnate Pharma Presents Data From Ongoing Phase 2 TELLOMAK Trial Demonstrating Clinical Activity of Lacutamab in Advanced Sézary Syndrome at ASH 2022
finance.yahoo.com - December 10 at 10:39 AM
finance.yahoo.com logoNumber of Shares and Voting Rights of Innate Pharma as of December 1, 2022
finance.yahoo.com - December 9 at 2:48 AM
markets.businessinsider.com logoKepler Capital Keeps Their Hold Rating on Innate Pharma SA (IPHYF)
markets.businessinsider.com - September 25 at 3:24 AM
seekingalpha.com logoInnate Pharma S.A. 2022 Q2 - Results - Earnings Call Presentation
seekingalpha.com - September 16 at 9:35 PM
finance.yahoo.com logoEdited Transcript of IPH.PA earnings conference call or presentation 15-Sep-22 12:00pm GMT
finance.yahoo.com - September 16 at 12:08 AM
seekingalpha.com logoInnate Pharma S.A. (IPHA) First Half 2022 Financial Results and Business Update Transcript
seekingalpha.com - September 15 at 7:07 PM
finance.yahoo.com logoInnate Pharma Reports First Half 2022 Financial Results and Business Update
finance.yahoo.com - September 15 at 1:27 AM
finance.yahoo.com logoInnate Pharma Announces Conference Call and Webcast for First Half 2022 Business Update
finance.yahoo.com - September 8 at 2:06 AM
finance.yahoo.com logoNumber of Shares and Voting Rights of Innate Pharma as of August 1, 2022
finance.yahoo.com - August 8 at 3:50 AM
Get Innate Pharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for IPHYF and its competitors with MarketBeat's FREE daily newsletter.

Start loving Mondays like this (Ad)

Wouldn’t you love to start looking forward to Mondays? We’re in a New Paradigm Shift in the market that could make it possible! You see, rallies over the weekends have become much more common in the last few years. Imagine hitting a few buttons on your phone or laptop to place a quick trade before the weekend hits… And coming back on Monday to what could be extra income sitting in your account… Weekend after weekend!

Weekend after weekend!

IPHYF Media Mentions By Week

IPHYF Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

IPHYF
News Sentiment
▼
1.30

0.53
▲
Average
Medical
News Sentiment

IPHYF News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

IPHYF Articles
This Week
▼
1

0
▲
IPHYF Articles
Average Week

Get Innate Pharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for IPHYF and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools

Related Companies:
Headlines Tools:
This page (OTCMKTS:IPHYF) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners
Healthcare Takes A Big Step Forward With The Help Of AI
The Bull Report
The Best AI Stock to Own in the World Today is Trading for Just $25
Banyan Hill Publishing
The “Perfect Storm” for Gold
Gold Safe Exchange
Biden’s $374B Giveaway Into This Sector
DTI
Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS
Paradigm Press
Your Money is Not Safe
American Alternative
He Is Giving Away Bitcoin
Crypto Swap Profits
The "Smart Money" Is Ready for May 1st Are You?
Stansberry Research